Dr Pasquale Rescigno is Clinical Senior Lecturer at the Translational and Clinical Research Institute at Newcastle University, UK. He is the former Head of the Translational and Clinical Trial Team on GU Cancers at the Istituto di Candiolo FPO-IRCCS (Candiolo Cancer Institute), Clinical Research Fellow at the Institute of Cancer Research (London), and Prostate Cancer Foundation Young Investigator awardee.  

His research mainly focuses on the study of mechanisms/pathways that are disrupted in prostate cancer (such as PTEN/PI3K/AKT, TP53 and RB1), and on the identification and validation of predictive, prognostic and efficacy-response biomarkers for novel agents targeting the PI3K/AKT, DNA repair systems and the PD-1/PDL-1 pathways.

He has served as Principal and Sub-investigator of several phase I/II/III Clinical Trials and designed and is the Clinical Coordinator and Principal Investigator of UK and Italian national research projects (MAESTRO, an umbrella trial and PERSEUS1 in the UK; BITCOIN and BRIDGE in Italy).

More recently, his research activity focused on the study of gut microbiome in prostate cancer.